Researchers at Leipzig University have identified GPR133, a member of the adhesion G protein-coupled receptor family, as a potential target for osteoporosis treatment. The study found that genetic impairment of GPR133 in mice leads to early-onset bone density loss, mirroring human osteoporosis. Using AP503, a compound recently discovered through computer-assisted screening as a GPR133 stimulator, the researchers significantly increased bone strength in both healthy and osteoporotic mice.

Activation of GPR133 by AP503 shifts the balance between bone-forming osteoblasts and bone-resorbing osteoclasts, favoring bone formation and reducing bone breakdown. This mechanism suggests that AP503 could be used to enhance bone strength or restore weakened bone, potentially benefiting conditions such as menopause-associated osteoporosis. Additionally, prior research by the same team indicates that AP503 may also strengthen skeletal muscle, highlighting its potential for addressing age-related declines in both bone and muscle tissue. The Leipzig University researchers are pursuing further studies to elucidate GPR133’s functions and explore AP503’s broader therapeutic applications. Source

This is a summary. Read the original at sciencedaily.com.